135605-97-9

Upstream product

• 619-73-8 4-nitrobenzyl chloride 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 288-32-4 1H-imidazole 
• 4457-41-4 4-nitrobenzyl benzoate 
• 619-90-9 4-nitrobenzyl acetate 
• 29681-57-0 tert-butyldimethylsilane 
• 555-16-8 4-nitrobenzaldehdye 

Downstream Products

• 555-16-8 4-nitrobenzaldehdye 
• 131230-76-7 4-[(tert-butyldimethylsilyloxy)methyl]aniline 
• 619-73-8 4-nitrobenzyl chloride 
• 1426551-42-9 N-(4-(hydroxymethyl)phenyl)-3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide 
• 1380070-92-7 N-benzyl-4-((tert-butyldimethylsilyloxy)methyl)aniline 
• 229005-80-5 TAK-779 
• 229008-29-1 N-(4-hydroxymethylphenyl)-2-(4-methylphenyl)-6,7-dihydro-5H-benzocycloheptene-8-carboxamide 
• 229008-30-4 N-(4-chloromethylphenyl)-2-(4-methylphenyl)-6,7-dihydro-5H-benzocycloheptene-8-carboxamide 

Relevant academic research and scientific papers

Ortho-dithiol reactive treatment probe for drug release monitoring and preparation method of ortho-dithiol reactive treatment probe

The invention discloses an ortho-dithiol reactive treatment probe for drug release monitoring and a preparation method of the ortho-dithiol reactive treatment probe. The structure of a probe compound is shown as a formula I in the specification. A probe m

BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF

The present invention relates to novel bioprobes which are capable of binding to certain amine oxidase enzymes. These bioprobes are useful in methods of detecting and determining the concentration of certain amine oxidase enzymes in a sample as well as in methods for the quantitative assessment of inhibition of certain amine oxidases.

COMPOUND HAVING BENZO SEVEN-MEMBERED RING STRUCTURE, PREPARATION METHOD THEREFOR, AND USE THEREOF

The present invention relates to a compound having a benzo seven-membered ring structure, and a preparation method therefor, and use thereof. The compound has a structure as represented by formula (I). Provided is use of the compound having the structure and prepared with the preparation method of the present invention, enantiomers, diastereomers, racemates and mixtures thereof of the compound, as well as chemically acceptable salts, crystalline hydrates and solvent mixtures of the compound and the enantiomers, diastereomers, racemates and mixtures thereof of the compound in the preparation of drugs for treating BET Bromodomain BRD4 activity or expression level related diseases.

KMnO4-catalyzed chemoselective deprotection of acetate and controllable deacetylation-oxidation in one pot

A novel and efficient protocol for chemoselective deacetylation under ambient conditions was developed using catalytic KMnO4. The stoichiometric use of KMnO4 highlighted the dual role of a heterogeneous oxidant enabling direct access to aromatic aldehydes in one-pot sequential deacetylation-oxidation. The reaction employed an alternative solvent system and allowed the clean transformation of benzyl acetate to sensitive aldehyde in a single step while preventing over-oxidation to acids. Use of inexpensive and readily accessible KMnO4 as an environmentally benign reagent and the ease of the reaction operation were particularly attractive, and enabled the controlled oxidation and facile cleavage of acetate in a preceding step. This journal is

METHOD OF PREPARING (3R,5R)-7-(2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4-((4-HYDROXYMETHYLPHENYLAMINO)CARBONYL)-PYRROL-1-YL)-3,5-DIHYDROXY-HEPTANOIC ACID HEMI CALCIUM SALT, INTERMEDIATES USED THEREIN, AND METHOD OF PREPARING THE INTERMEDIATES

The present invention provides a method for manufacturing a (3r,5r)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxymethylphenylamino)carbonyl)-pyrrol-1-yl)-3,5-dihydroxy-heptanoic acid hemi-calcium salt, an intermediate thereof, and a manufacturing method thereof. According to the present invention, the manufacturing method is performed in a convergent synthesis method of individually synthesizing each main structural part of the (3r,5r)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxymethylphenylamino)carbonyl)-pyrrol-1-yl)-3,5-dihydroxy-heptanoic acid hemi-calcium salt and coupling the synthesized main structural parts. Accordingly, a flexible material can be easily controlled and manufacturing time can be reduced, thereby increasing productivity of a compound and yield of the final compound.COPYRIGHT KIPO 2019

CYCLOPENTAIMIDAZOLONES FOR THE TREATMENT OF CANCER

Provided herein are compounds useful for the treatment of various proliferative diseases. These compounds, as well as pharmaceutically acceptable salts thereof may be formulated in pharmaceutical compositions, and may be used in methods of treatment and/o

Oxidative Cleavage of Silyl Ethers by an Oxoammonium Salt

A method for the oxidative cleavage of silyl ethers to their corresponding carbonyl species mediated by an oxoammonium salt is described. The resulting aldehydes and ketones are obtained under mild reaction conditions with no observed overoxidation. For robust substrates, heating to reflux temperatures significantly reduces the reaction time.

A DT-diaphorase responsive theranostic prodrug for diagnosis, drug release monitoring and therapy

A DT-diaphorase-activatable theranostic prodrug, which contains camptothecin, a self-immolative linker and a trigger group, has been developed for the detection of DT-diaphorase, tracking of drug release and selectively killing cancer cells over-expressed

1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT

The invention provides antibody-drug conjugates comprising an antibody conjugated to a 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimer drug moiety via a linker, and methods of using the antibody-drug conjugates.

Lewis acidity of bis(perfluorocatecholato)silane: Aldehyde hydrosilylation catalyzed by a neutral silicon compound

Bis(perfluorocatecholato)silane Si(catF)2 was prepared, and stoichiometric binding to Lewis bases was demonstrated with fluoride, triethylphosphine oxide, and N,N′-diisopropylbenzamide. The potent Lewis acidity of Si(catF)2 was suggested from catalytic hydrosilylation and silylcyanation reactions with aldehydes. Mechanistic studies of hydrosilylation using an optically active silane substrate, R-(+)-methyl-(1-naphthyl)phenylsilane, proceeded with predominant stereochemical retention at silicon, consistent with a carbonyl activation pathway. The enantiospecificity was dependent on solvent and salt effects, with increasing solvent polarity or addition of NBu4BArF4 leading to a diminished enantiomeric ratio. The medium effects are consistent with an ionic mechanism, wherein hydride transfer occurs prior to silicon-oxygen bond formation.